ABBVIE

DelveInsight's 'Ankylosing Spondylitis Pipeline Insight, 2024' report details the clinical development scenario and growth prospects across the Ankylosing Spondylitis market, covering 20+ key companies and 20+ treatment therapies. The report includes insights on clinical trials, therapies, mechanism of action, route of administration, and developments, with a focus on emerging therapies like KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, and Apremilast. Key companies include Pfizer, UCB Biopharma, Fresenius Kabi, and Shanghai Henlius.

Alector's AL002 failed Phase II INVOKE-2 study for Alzheimer’s, showing no significant clinical progression slowdown. The study revealed safety issues with ARIA and infusion-related reactions. Alector's stock dropped 31% post-announcement, leading to a resource realignment initiative including layoffs of 17% of the workforce. The company will focus on AL001 and its blood-brain-barrier platform.

DelveInsight's report on Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034 details the market size, emerging therapies, and key companies like Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma, Gilead Sciences, Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others. The market size in 7MM was ~USD 9,000 million in 2023, expected to increase by 2034, with key therapies like ENTYVIO, STELARA, VELSIPITY, Zeposia, LY-3074828, RHB-104, and others expected to launch. Positive results for mirikizumab and TREMFYA were reported in 2024, and Dong-A-ST's Imuldosa received FDA approval as a biosimilar to Stelara.

The article discusses the importance of enabling JavaScript for optimal app performance.

Trump's cabinet nominees aim to drastically cut federal spending and government workforce, with Elon Musk and Vivek Ramaswamy planning to slash $500 billion. Trump also proposed closing the Department of Education, naming Linda McMahon as secretary. Dr. Mehmet Oz and Robert F. Kennedy Jr. were nominated for CMS and HHS, respectively, with plans to tackle chronic diseases and potentially alter Medicare drug price negotiation and NIH operations. Kennedy seeks to ban pharmaceutical advertising on TV, while Oz advocates for expanding Medicare Advantage plans.

Slone Partners assisted in recruiting Amy Nicole Nayar as the new president and CEO of the Personalized Medicine Coalition (PMC), effective January 1, 2025. Nayar, with over 25 years in global health, will focus on expanding PMC's influence in education, advocacy, and evidence development for personalized medicine.

The global biopharmaceuticals market is projected to reach USD 566 billion by 2032, driven by innovations in treating previously untreatable diseases. North America led in 2022 with a 43% share. Key players like Pfizer and InflaRx are advancing therapies, but challenges include high costs and regulatory complexities. The industry is also focusing on sustainability and digital transformation.

Astellas Pharma received a Complete Response Letter from the FDA for avacincaptad pegol, while Aldeyra Therapeutics' topical reproxalap for dry eye disease had its NDA accepted. Dr. Valerie Biousse discussed the benefits of non-mydriatic fundus cameras in emergency departments, enabling remote diagnosis and reducing ED length of stay. Dr. Jonathan Brugger highlighted the correlation between energy drink consumption and retinal vein occlusions in young adults.

US FDA issues Complete Response Letter for avacincaptad pegol (IZERVAY) due to a statistical matter; Aldeyra Therapeutics' NDA for reproxalap for dry eye accepted by FDA; case report on carotid-cavernous fistula misdiagnosed as allergies; AAOpt 2024 discusses genetic testing; study links long-term blood pressure variability to visual field progression in glaucoma.

FDA approved zolbetuximab-clzb (Vylov) plus chemotherapy for HER2-negative, CLDN18.2-positive gastric/GEJ adenocarcinoma, addressing unmet need in PD-L1–low/HER2-negative patients. Routine CLDN18.2 testing is crucial for targeted therapy in previously non-targetable populations.